Search Results
256 Results Found for “epidermal growth factor receptor”
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2 Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3 Currently, it has the ...
The European Society for Medical Oncology (ESMO) 2025 congress brought over 100 late-breaking abstracts, 250 sessions, 600 expert speakers and 33,800 delegates to Berlin in October. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of oncology practice.
“ESMO 2025 felt like a true turning point in breast cancer care” At the European Society for Medical Oncology (ESMO) 2025 congress, the landscape of early and advanced breast cancer management was powerfully reshaped, with new data spanning hormone-receptor positive (HR+), human ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
At WCLC 2025, final FLAURA2 results revealed that osimertinib plus chemotherapy significantly improves overall survival in EGFR-mutant advanced non-small cell lung cancer (NSCLC), extending median survival to nearly four years. Experts stress the practice-changing impact, while highlighting the importance of tailoring treatment to patient fitness, comorbidities, and individual goals.
Dr Federico Monaca discusses the role of consolidative thoracic radiotherapy after chemo-immunotherapy in ES-SCLC, highlighting improved chest control but uncertain survival impact. He also reflects on key WCLC 2025 updates, including DLL3-targeted therapies, novel immunotherapy combinations, and biomarker-driven strategies offering fresh hope in small cell and non-small cell lung cancers.
Dr Igor Gómez-Randulfe discusses new real-world evidence on second-line carboplatin plus pemetrexed after osimertinib in EGFR-mutant NSCLC. The retrospective analysis highlights modest response rates and short overall survival, reinforcing the need for more effective strategies and raising critical questions about sequencing, intensification, and resistance profiling.
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2 Even though the adoption of both primary (HPV ...
With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.
The VERITAC-2 trial is a pivotal, randomized phase III trial evaluating vepdegestrant, a novel oral PROTAC estrogen receptor degrader, in patients with ER-positive, HER2-negative advanced breast cancer. In this interview, Dr Erika Hamilton (Director, Breast Cancer Research, Sarah Cannon ...
DESTINY-Breast09 interim results show that trastuzumab deruxtecan plus pertuzumab significantly improves progression-free survival compared to standard THP in first-line treatment for metastatic HER2-positive breast cancer. With a median PFS of 40.7 months versus 26.9 months, the data suggest a potential shift in the treatment paradigm.
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1 Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2 Head and neck squamous cell carcinoma (...
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
